AMX-3009 is under clinical development by Arromax Pharmatech and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMX-3009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
AMX-3009 is under development for the treatment of HER2 positive and over expressing solid tumors including breast cancer, gastric cancer and lung cancer. It is a quinazoline derivative and acts by targeting EGFR and HER2. It is administered through oral route.
Arromax Pharmatech overview
Arromax Pharmatech is a pharmaceutical company engaged in research and development of generic drugs. The company researches and develops generic drug synthesis process in the areas of anti-tumor, cardiovascular and diabetes. Its products include montelukast sodium, rivaroxaban, ticagrelor, ezetimibe, capecitabine, sitagliptin, apixaban, crizotinib, and others. Arromax Pharmatech provides custom synthesis, process development, and drug quality studies and establishment of quality standards of new drugs. The company serves client such as chemical manufacturing companies and academic research institutes to provides hetero-aromatic products. It also offers APIs and their key intermediates. The company runs its operation in India and China. Arromax Pharmatech is headquartered in Suzhou, China.
For a complete picture of AMX-3009’s drug-specific PTSR and LoA scores, buy the report here.